CDEK
← All drugs Report issue

capreomycin

Trade name: capastat

Small moleculeapproved

Approved

Jun 2, 1971

Capreomycin is an antibiotic, which is used in combination other antituberculosis drugs fro the treatment of pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins. — NCATS

Clinical trial activity

3 trials · 5 clinical orgs · 6 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1

Earliest trial started Nov 2, 1999 (NCT00000796)

Timeline

1970s

  1. Jun 2, 1971

    Earliest FDA Approval

  2. Jun 2, 1971

    Akorn, Inc. — NDA Secondary Org

  3. Jun 2, 1971

    Epic Pharma Llc — Marketing Organization

2010s

  1. Nov 27, 2017

    Mylan — Marketing Organization

  2. Nov 27, 2017

    PHARMOBEDIENT — Marketing Organization

  3. Oct 18, 2018

    Zhejiang Hisun Pharmaceutical Co. Ltd. — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 2, 1971

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1
Mol. weight
1321.44 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 34977
  • capastat
  • capastat
  • capastat
  • capastat
  • capastat sulfate
  • capostatin
  • capreomicin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycin
  • capreomycine
  • capreomycine
  • capreomycine
  • capreomycine sulfate
  • capreomycin sulfate
  • capreomycin sulfate
  • capreomycin sulfate
  • capreomycin sulfate
  • capreomycin sulfate
  • capromycin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02236078N/ANov 1, 2015Centers for Disease Control and Prevention (CDC), Kenya Medical Research Institute
NCT00042289Phase 4Mar 1, 2003Boston University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
NCT00000796N/ANov 2, 1999National Institute of Allergy and Infectious Diseases (NIAID)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government2221999
Boston UniversityAcademic/Hospital1012003
Centers for Disease Control and Prevention (CDC)Government1112015
Kenya Medical Research InstituteAcademic/Hospital1012015
National Institutes of Health (NIH)Government1012003
5 organizations
Page 1 / 1

Marketing (6)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitNDA2Jun 2, 1971
Eli LillyFor profitNDA—
Epic Pharma LlcFor profitMKTGJun 2, 1971
MylanFor profitMKTGNov 27, 2017
PHARMOBEDIENTFor profitMKTGNov 27, 2017
Zhejiang Hisun Pharmaceutical Co. Ltd.For profitMKTGOct 18, 2018